Overview

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
Phase:
Phase 4
Details
Lead Sponsor:
Jazz Pharmaceuticals